|
Oct 8
|
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
|
|
Sep 13
|
Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024
|
|
Jul 23
|
Ensysce Biosciences Provides Mid-Year 2024 Update
|
|
Jun 25
|
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
|
|
Jun 6
|
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
|
|
May 28
|
Ensysce Biosciences Regains Compliance with Nasdaq
|
|
May 14
|
Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
|
May 13
|
Ensysce Biosciences Reports First Quarter 2024 Financial Results
|
|
May 13
|
ENSC: Quarterly Report Highlights Progress
|
|
Apr 25
|
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
|
|
Apr 19
|
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
|
|
Apr 9
|
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
|
|
Mar 15
|
ENSC Striding Toward Opioid Replacement
|
|
Mar 15
|
Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 8
|
Ensysce Biosciences Issues 2024 Shareholder Letter
|
|
Dec 19
|
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
|
|
Dec 14
|
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
|
|
Dec 11
|
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
|
|
Nov 29
|
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
|
|
Nov 28
|
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
|